Literature DB >> 10434311

CAG repeat instability, cryptic sequence variation and pathogeneticity: evidence from different loci.

M Frontali1, A Novelletto, G Annesi, C Jodice.   

Abstract

Different aspects of expanded polyglutamine tracts and of their pathogenetic role are taken into consideration here. (i) The (CAG)n length of wild-type alleles of the Huntington disease gene was analysed in instability-prone tumour tissue from colon cancer patients to test whether the process leading to the elongation of alleles towards the expansion range involves single-unit stepwise mutations or larger jumps. The analysis showed that length changes of a single unit had a relatively low frequency. (ii) The observation of an expanded spinocerebellar ataxia (SCA)1 allele with an unusual pattern of multiple CAT interruptions showed that cryptic sequence variations are critical not only for sequence length stability but also for the expression of the disease phenotype. (iii) Small expansions of the (CAG)n sequence at the CACNA1A gene have been reported as causing SCA6. The analysis of families with SCA6 and episodic ataxia type 2 showed that these phenotypes are, in fact, expressions of the same disorder caused either by point mutations or by small (CAG)n expansions. A gain of function has been hypothesized for all proteins containing an expanded polyglutamine stretch, including the alpha 1A subunit of the voltage-gated calcium channel type P/Q coded by the CACNA1A gene. Because point mutations at the same gene with similar phenotypic consequences are highly unlikely to have this effect, an alternative common pathogenetic mechanism for all these mutations, including small expansions, can be hypothesized.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10434311      PMCID: PMC1692606          DOI: 10.1098/rstb.1999.0464

Source DB:  PubMed          Journal:  Philos Trans R Soc Lond B Biol Sci        ISSN: 0962-8436            Impact factor:   6.237


  35 in total

1.  A novel CAG repeat configuration in the SCA1 gene: implications for the molecular diagnostics of spinocerebellar ataxia type 1.

Authors:  F Quan; J Janas; B W Popovich
Journal:  Hum Mol Genet       Date:  1995-12       Impact factor: 6.150

2.  Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3.

Authors:  H L Paulson; M K Perez; Y Trottier; J Q Trojanowski; S H Subramony; S S Das; P Vig; J L Mandel; K H Fischbeck; R N Pittman
Journal:  Neuron       Date:  1997-08       Impact factor: 17.173

3.  Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats.

Authors:  G Imbert; F Saudou; G Yvert; D Devys; Y Trottier; J M Garnier; C Weber; J L Mandel; G Cancel; N Abbas; A Dürr; O Didierjean; G Stevanin; Y Agid; A Brice
Journal:  Nat Genet       Date:  1996-11       Impact factor: 38.330

4.  Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4.

Authors:  R A Ophoff; G M Terwindt; M N Vergouwe; R van Eijk; P J Oefner; S M Hoffman; J E Lamerdin; H W Mohrenweiser; D E Bulman; M Ferrari; J Haan; D Lindhout; G J van Ommen; M H Hofker; M D Ferrari; R R Frants
Journal:  Cell       Date:  1996-11-01       Impact factor: 41.582

5.  Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel.

Authors:  O Zhuchenko; J Bailey; P Bonnen; T Ashizawa; D W Stockton; C Amos; W B Dobyns; S H Subramony; H Y Zoghbi; C C Lee
Journal:  Nat Genet       Date:  1997-01       Impact factor: 38.330

6.  Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo.

Authors:  E Scherzinger; R Lurz; M Turmaine; L Mangiarini; B Hollenbach; R Hasenbank; G P Bates; S W Davies; H Lehrach; E E Wanker
Journal:  Cell       Date:  1997-08-08       Impact factor: 41.582

7.  Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation.

Authors:  S W Davies; M Turmaine; B A Cozens; M DiFiglia; A H Sharp; C A Ross; E Scherzinger; E E Wanker; L Mangiarini; G P Bates
Journal:  Cell       Date:  1997-08-08       Impact factor: 41.582

8.  Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue.

Authors:  S Zeitlin; J P Liu; D L Chapman; V E Papaioannou; A Efstratiadis
Journal:  Nat Genet       Date:  1995-10       Impact factor: 38.330

9.  Reduced penetrance of the Huntington's disease mutation.

Authors:  S M McNeil; A Novelletto; J Srinidhi; G Barnes; I Kornbluth; M R Altherr; J J Wasmuth; J F Gusella; M E MacDonald; R H Myers
Journal:  Hum Mol Genet       Date:  1997-05       Impact factor: 6.150

10.  Genetic fitness in Huntington's Disease and Spinocerebellar Ataxia 1: a population genetics model for CAG repeat expansions.

Authors:  M Frontali; G Sabbadini; A Novelletto; C Jodice; F Naso; M Spadaro; P Giunti; A G Jacopini; L Veneziano; E Mantuano; P Malaspina; L Ulizzi; A Brice; A Durr; L Terrenato
Journal:  Ann Hum Genet       Date:  1996-09       Impact factor: 1.670

View more
  10 in total

Review 1.  Molecular pathogenesis of spinocerebellar ataxia type 6.

Authors:  Holly B Kordasiewicz; Christopher M Gomez
Journal:  Neurotherapeutics       Date:  2007-04       Impact factor: 7.620

2.  Bicistronic CACNA1A Gene Expression in Neurons Derived from Spinocerebellar Ataxia Type 6 Patient-Induced Pluripotent Stem Cells.

Authors:  Carlo Bavassano; Andreas Eigentler; Ruslan Stanika; Gerald J Obermair; Sylvia Boesch; Georg Dechant; Roxana Nat
Journal:  Stem Cells Dev       Date:  2017-10-30       Impact factor: 3.272

3.  The impact of ataxin-1-like histidine insertions on polyglutamine aggregation.

Authors:  Murali Jayaraman; Ravindra Kodali; Ronald Wetzel
Journal:  Protein Eng Des Sel       Date:  2009-06-18       Impact factor: 1.650

4.  Complete loss of P/Q calcium channel activity caused by a CACNA1A missense mutation carried by patients with episodic ataxia type 2.

Authors:  S Guida; F Trettel; S Pagnutti; E Mantuano; A Tottene; L Veneziano; T Fellin; M Spadaro; K Stauderman; M Williams; S Volsen; R Ophoff; R Frants; C Jodice; M Frontali; D Pietrobon
Journal:  Am J Hum Genet       Date:  2001-02-01       Impact factor: 11.025

5.  Correlation of inter-locus polyglutamine toxicity with CAG•CTG triplet repeat expandability and flanking genomic DNA GC content.

Authors:  Colm E Nestor; Darren G Monckton
Journal:  PLoS One       Date:  2011-12-06       Impact factor: 3.240

Review 6.  Expansion, mosaicism and interruption: mechanisms of the CAG repeat mutation in spinocerebellar ataxia type 1.

Authors:  Cara Kraus-Perrotta; Sarita Lagalwar
Journal:  Cerebellum Ataxias       Date:  2016-11-22

Review 7.  Ubiquitin, Autophagy and Neurodegenerative Diseases.

Authors:  Yoshihisa Watanabe; Katsutoshi Taguchi; Masaki Tanaka
Journal:  Cells       Date:  2020-09-02       Impact factor: 6.600

Review 8.  Molecular mechanism of Spinocerebellar Ataxia type 6: glutamine repeat disorder, channelopathy and transcriptional dysregulation. The multifaceted aspects of a single mutation.

Authors:  Paola Giunti; Elide Mantuano; Marina Frontali; Liana Veneziano
Journal:  Front Cell Neurosci       Date:  2015-02-16       Impact factor: 5.505

9.  The role of interruptions in polyQ in the pathology of SCA1.

Authors:  Rajesh P Menon; Suran Nethisinghe; Serena Faggiano; Tommaso Vannocci; Human Rezaei; Sally Pemble; Mary G Sweeney; Nicholas W Wood; Mary B Davis; Annalisa Pastore; Paola Giunti
Journal:  PLoS Genet       Date:  2013-07-25       Impact factor: 5.917

10.  Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and mice.

Authors:  Christian Barro; Jeannette Hübener-Schmid; Matthis Synofzik; Carlo Wilke; Eva Haas; Kathrin Reetz; Jennifer Faber; Hector Garcia-Moreno; Magda M Santana; Bart van de Warrenburg; Holger Hengel; Manuela Lima; Alessandro Filla; Alexandra Durr; Bela Melegh; Marcella Masciullo; Jon Infante; Paola Giunti; Manuela Neumann; Jeroen de Vries; Luis Pereira de Almeida; Maria Rakowicz; Heike Jacobi; Rebecca Schüle; Stephan A Kaeser; Jens Kuhle; Thomas Klockgether; Ludger Schöls
Journal:  EMBO Mol Med       Date:  2020-06-08       Impact factor: 12.137

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.